(Q33484119)

27 July 2017

1 reference

title

A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus (English)

1 reference

27 July 2017

1 reference

F Santeusanio

1

1 reference

27 July 2017

P Compagnucci

series ordinal

2

1 reference

27 July 2017

publication date

1 December 1994

1 reference

27 July 2017

1 reference

27 July 2017

volume

11

1 reference

27 July 2017

issue

6

1 reference

27 July 2017

page(s)

432-444

1 reference

Oral antidiabetic agents. The emergence of alpha-glucosidase inhibitors

27 July 2017

cites work

1 reference

12 December 2020

Insulin resistance and blood pressure in young black men.

1 reference

12 December 2020

The diabetes control and complications trial. Implications for policy and practice

1 reference

12 December 2020

Inhibition of disaccharide digestion in rat intestine by the alpha-glucosidase inhibitor acarbose (BAY g 5421)

1 reference

12 December 2020

Implications of the Diabetes Control and Complications Trial. American Diabetes Association

1 reference

12 December 2020

Insulin resistance in essential hypertension

1 reference

12 December 2020

Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment

1 reference

12 December 2020

Heterogeneity of insulin responses: phases leading to type 2 (non-insulin-dependent) diabetes mellitus in the rhesus monkey.

1 reference

12 December 2020

Safety Profile of Acarbose, an α-Glucosidase Inhibitor

1 reference

12 December 2020

Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NIDDM)

1 reference

12 December 2020

Influence of acarbose on hyperglycemia induced by various carbohydrates in rats and oral starch tolerance in monkeys

1 reference

12 December 2020

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

12 December 2020

Reappraisal of the role of insulin in hypertriglyceridemia.

1 reference

12 December 2020

A glycoside-hydrolase inhibitor in treatment of dumping syndrome

1 reference

12 December 2020

Enteroglucagon release in disaccharide malabsorption induced by intestinal alpha-glucosidase inhibition

1 reference

12 December 2020

alpha-Glucosidase inhibition in obesity.

1 reference

12 December 2020

Effects of the disaccharidase inhibitor acarbose on meal and intravenous glucose tolerance in normal man

1 reference

12 December 2020

Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes.

1 reference

12 December 2020

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

1 reference

12 December 2020

The physiology and pathophysiology of gastric emptying in humans

1 reference

12 December 2020

Influence of an ??-amylase inhibitor (BAY d 7791) on blood glucose, serum insulin and nefa in starch loading tests in rats, dogs and man

1 reference

12 December 2020

Lower triglyceride production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor

1 reference

12 December 2020

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man

1 reference

12 December 2020

Acarbose treatment of non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Satiety in the obese Zucker rat: effects of carbohydrate type and acarbose (Bay g 5421).

1 reference

12 December 2020

New concepts in the pathogenesis and treatment of noninsulin-dependent diabetes mellitus

1 reference

12 December 2020

The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism?

1 reference

12 December 2020

Early Phase of Insulin Release

1 reference

12 December 2020

Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus

1 reference

12 December 2020

Inhibition of carbohydrate-induced hypertriglyceridemia by a disaccharidase inhibitor

1 reference

12 December 2020

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

12 December 2020

Decreased Sensitivity of the Pancreatic Beta Cells to Glucose in Prediabetic and Diabetic Subjects: A Glucose Dose-Response Study

1 reference

12 December 2020

Effect of acarbose on biochemical responses and clinical symptoms in dumping syndrome

1 reference

12 December 2020

Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes

1 reference

12 December 2020

Hyperglycemia alters the physico-chemical properties of proteins in erythrocyte membranes of diabetic patients

1 reference

12 December 2020

Modification of weight gain by an alpha-glucosidase inhibitor during refeeding in rats

1 reference

12 December 2020

Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin.

1 reference

12 December 2020

Type II Diabetes and Syndrome X: Pathogenesis and Glycemic Management

1 reference

12 December 2020

Optimum effectiveness of intestinal alpha-glucosidase inhibitors: importance of uniform distribution through a meal

1 reference

12 December 2020

Effects of an α-Glucosidase Inhibitor, Acarbose, on Blood Glucose and Serum Lipids in Streptozotocin-Induced Diabetic Rats

1 reference

12 December 2020

Treatment of non-insulin dependent diabetic adults with a new glycoside hydrolase inhibitor (Bay g 5421)

1 reference

12 December 2020

Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas.

1 reference

12 December 2020

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

1 reference

12 December 2020

Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes

1 reference

12 December 2020

Effects of acarbose on the relationship between changes in GIP and insulin responses to meals in normal subjects

1 reference

12 December 2020

Preventing long term complications. Implications for combination therapy with acarbose

1 reference

12 December 2020

Effects of acarbose on starch hydrolysis. Study in healthy subjects, ileostomy patients, and in vitro

1 reference

12 December 2020

Acarbose in reactive hypoglycemia: a double-blind study

1 reference

12 December 2020

Scope and specificity of acarbose in slowing carbohydrate absorption in man

1 reference

12 December 2020

Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis

1 reference

12 December 2020

Insulin and atheroma. 20-yr perspective

1 reference

12 December 2020

Insulin resistance--mechanisms, syndromes, and implications

1 reference

12 December 2020

A new approach to the treatment of nocturnal hypoglycemia using alpha-glucosidase inhibition

1 reference

12 December 2020

▼Acarbose for non-insulin-dependent diabetes mellitus

1 reference

12 December 2020

Acute and short term effects of intestinal alpha-glucosidase inhibition on gut hormone responses in man

1 reference

12 December 2020

Fate and effects of the alpha-glucosidase inhibitor acarbose in humans. An intestinal slow-marker perfusion study

1 reference

12 December 2020

Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus

1 reference

12 December 2020

The effect of short-term alpha-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics.

1 reference

12 December 2020

Metabolic effects of acarbose in young healthy men.

1 reference

12 December 2020

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in man

1 reference

12 December 2020

Effect of the?? glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics

1 reference

12 December 2020

Changes in plasma lipoprotein levels during medication with a glucoside-hydrolase inhibitor (acarbose)

1 reference

12 December 2020

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

12 December 2020

The use of acarbose in the primary-care setting: evaluation of efficacy and tolerability of acarbose by postmarketing surveillance study

1 reference

12 December 2020

Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non insulin dependent (type II) diabetes mellitus

1 reference

12 December 2020

Manipulation of gut hormone response to food by soluble fiber and alpha-glucosidase inhibition

1 reference

12 December 2020

Response of serum levels of gastric inhibitory polypeptide and insulin to sucrose ingestion during long-term application of acarbose

1 reference

12 December 2020

Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study

1 reference

12 December 2020

10.2165/00002018-199411060-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

27 July 2017

1002427478

0 references

1 reference